Toll Free: +1-888-717-2436


Your Shopping Cart

Contains 0 items
Total: $0.00
View Shopping Cart
Cart Image

customer care
Fax: +1-650-963-2556
Read Frequently Asked Questions

Critical Compliance and Major Changes for the EU Clinical Trials Directive

Buy Now Section

This EU Clinical Trials Directive training will cover major changes to compliance requirements concerning the Clinical Trial Directive that you should know to get your trial approved or run clinical trials to meet EU requirements.

Instructor: Laura Brown
Product ID: 702092

Why Should You Attend:

This presentation will discuss the key requirements of the European Clinical Trials Directive 2001/20/EC and the important proposed changes.

This presentation will explain the framework of documents, provided in the Clinical Trials Directive, which sets out how clinical trials must be conducted. We will discuss how the Directive was further expanded by Commission Directive 2005/28/EC of laying down principles and detailed guidelines for good clinical practice as regards investigational medicinal products for human use, as well as the requirements for authorisation of the manufacturing or importation of such products" (Good Clinical Practice - " the GCP Directive").

This presentation will also discuss in what ways the Clinical Trials Directive is currently undergoing a major consultation process to try to overcome some of the key challenges of working to the Directive.

Areas Covered in the Seminar:

Who Will Benefit:

This webinar will provide critical assistance to FDA and EMA regulated companies currently carrying out or preparing to conduct clinical trials for pharmaceutical, and biopharmaceuticals

Instructor Profile:

Dr. Laura Brown , PhD, MBA, Diploma Clinical Sciences is an independent QA and Training Consultant in the Pharmaceutical Industry, and Course Director for the MSc in Clinical Research, School of Pharmacy at the University of Cardiff. Laura has more than 17 years experience of running clinical trials and clinical quality assurance in the pharmaceutical industry. She has held a number of international and senior management QA positions in the pharmaceutical industry including as an Associate Director with a leading GCP audit consultancy. She has worked for several international companies including GlaxoWellcome, Hoechst Marion Roussel and Phoenix International.

Laura is author of a chapter on “Training QA staff” in the leading GXP book: “Good Clinical, Laboratory and Manufacturing Practices” (2007). She is author of SCRIP's latest GCP guide and a “Practical Guide to the Clinical Trial Directive. She is also co-author of several books including “Developing the Individual” and “Project Management for the Pharmaceutical Industry”. She has regularly lectured at conferences and on training courses on QA and GCP issues.

Laura runs many training courses both on public courses and in-company on topics including: pharmaceutical project management, understanding the pharmaceutical industry/drug development, writing and managing SOPs, GCP , the clinical trial directive, managing clinical trials, QA Management and business skills, how to prepare for audit and inspection.

Topic Background:

The European Clinical Trials Directive 2001/20/EC was introduced to establish standardization of research activity in clinical trials throughout the European Community. The Directive was transposed into laws throughout the EU from 1st May 2004 and is going through possible major changes currently.

Clinical trials performed in the European Union are required to be conducted in accordance with the Clinical Trials Directive. Also, if the clinical trials are conducted outside the EU, but submitted in an application for marketing authorization in the EU, they should have to follow the principles which are equivalent to the provisions of the Clinical Trials Directive (cf. Annex I, point 8 of the " Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use" - " the Community Code for medicinal products ").

Follow us :
Bookmark and Share
Refund Policy
Registrants may cancel up to two working days prior to the course start date and will receive a letter of credit to be used towards a future course up to one year from date of issuance.
ComplianceOnline would process/provide refund if the Live Webinar has been cancelled. The attendee could choose between the recorded version of the webinar or refund for any cancelled webinar. Refunds will not be given to participants who do not show up for the webinar. On-Demand Recordings can be requested in exchange.

Webinar may be cancelled due to lack of enrolment or unavoidable factors. Registrants will be notified 24hours in advance if a cancellation occurs. Substitutions can happen any time.

If you have any concern about the content of the webinar and not satisfied please contact us at below email or by call mentioning your feedback for resolution of the matter.

We respect feedback/opinions of our customers which enables us to improve our products and services. To contact us please email or call +1-888-717-2436(Toll Free).

COSO Framework for Internal Controls, Risk Assessment and Financial Statement Audit - 80225SEM

This training hasn't been reviewed yet.

Review this training

Training Options Training Duration = 60 Min
$299.00 Access Recorded Version Only
One Person - Unlimited viewing for 6 Months
(For multiple licenses contact Customer Care)
Recorded Link and Ref. material will be available in My CO Section
$499.00 Get Training CD Only
One CD is for usage in one location only.
(For multiple locations contact Customer Care)
CD and Ref. material will be shipped within 15 business days